Olmutinib
- Generic Name
- Olmutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26N6O2S
- CAS Number
- 1353550-13-6
- Unique Ingredient Identifier
- CHL9B67L95
- Background
Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the U...
- Indication
For use in treatment of metastatic T790M mutation positive non-small cell lung cancer .
- Associated Conditions
- -
- Associated Therapies
- -
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 2
- Registration Number
- NCT04510415
- Locations
- 🇰🇷
The Catholic Univ. of Korea St.Vincent's Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic Univ. of Korea Uijeongbu St.Mary's Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic Univ. of Korea Bucheon St.Mary's Hospital, Gyeonggi-do, Korea, Republic of
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03228277
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.